ArticleScientific reports2025
Performance of MRI-based radiomics for prediction of residual disease status in patients with nasopharyngeal carcinoma after radical radiotherapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Recent Advances in Surveillance Strategies for Nasopharyngeal Carcinoma.Current oncology reports · 2026Review
- Multi-habitat radiomics on T2-FS MRI for identifying spatial patterns of axial spondyloarthritis-associated bone marrow edema.Clinical rheumatology · 2026Article
- Article
- Habitat and peritumoral CT radiomics accurately predict early treatment response to hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and programmed death-1 inhibitors in unresectable hepatocellular carcinoma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to determine if habitat radiomic features extracted from pretherapy multi-sequence MRI predict residual status in patients with Nasopharyngeal Carcinoma (NPC) after radical radiotherapy. The retrospective study enrolled 179 primary NPC patients, divided into training and validation cohorts at a 7:3 ratio. K-means clustering was employed to segment T2WI, CE-T1WI and FSCE-T1WI images, creating habitats within the volume of interest. Identify relevant features that can recognize NPC residuals. In the training cohort, support vector machine (SVM) models were developed utilizing the radiomic features extracted from each habitat and the entire tumor, selecting the most predictive features for each sequence. SVM models were constructed by combining the optimal radiomic features from each sequences with clinical data. Model performance was compared and validated using receiver operating characteristic (ROC) curves, calibration curves and decision curve analysis (DCA), and differences between models were assessed using the DeLong test. The optimal clustering results revealed 4 habitats in FSCE-T1WI, while 2 habitats in both CE-T1WI and T2WI sequences. In the training cohort, we compared the predictive accuracy of SVM models based on different habitats and total tumor characteristics from three sequences, and found that the features from T2 Hab2, CE-T1 Hab1, and FSCE-T1 Hab4 images showed higher performance. Incorporation of habitat-based radiomic features and clinical variables significantly enhanced the predictive performance. The integrated model exhibits the optimal predictive performance, with the area under the curve (AUC) values of 0.921 (SEN = 0.821, SPE = 0.830) in the training cohort and 0.811 (SEN = 0.778, SPE = 0.722) in the validation cohort. Compared to conventional radiomics, habitat imaging features that distinguish intratumoral heterogeneity have higher predictive value, making them potential non-invasive biomarkers for assessing NPC residual after radiotherapy. Integration of multi-sequence MRI habitat radiomic with clinical parameters further improved predictive accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.